The global sexually transmitted diseases testing market size was estimated to be USD 9.61 billion in 2023 and is expected to reach at USD 23.50 billion by 2034 with a CAGR of 8.47% during the forecast period 2024-2034. The increasing prevalence of sexually transmitted diseases, heightened patient awareness facilitated by educational campaigns, growing governmental initiatives, rising advancements in STD diagnostics, a surge in research & development activities for innovative technologies, a notable transition from conventional methods to molecular diagnostics for STD diagnosis, growing introduction of novel testing options, and rising approvals of innovative testing products by regulatory authorities are some of the key factors boosting the market growth.
Rising approvals of innovative testing products by regulatory authorities is predicted to boost the market growth during the forecast period. Sexually Transmitted Diseases (STDs) are infections resulting from bacteria, viruses, or parasites that are transmitted through various forms of sexual contact, such as vaginal, anal, and oral sex. Additionally, they can be transmitted vertically from mother to child during pregnancy, childbirth, and breastfeeding. The objective of screening is to identify individuals in an apparently healthy population who face an elevated risk of a health issue or condition. This allows for early treatment or intervention, ultimately reducing the incidence and mortality rate within the population. For instance, in May 2022, Abbott's Alinity m STI Assay, capable of detecting and distinguishing four prevalent sexually transmitted infections (STIs), has received approval from the Food and Drug Administration.
By product, consumables was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the rising introduction of innovative solutions and increase in product approvals. For instance, in May 2022, Medmira Inc. has obtained the CE mark for its Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo TP/nTP). This certification empowers the company to enhance its product portfolio in markets that recognize the CE mark. Additionally, instruments & services is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for diagnostic testing kits and surge in research & development activities.
By diagnostic testing, laboratory testing was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the growing patient inclination towards independent clinical laboratories for the diagnosis of these illnesses, and increasing introductions of products in the molecular diagnostics sector enable laboratories to install instruments or equipment based on their specific requirements. For instance, in May 2022, NeuMoDxHSV 1/2 Quant Assay was introduced by Qiagen Inc. with European Commission clearance to measure and distinguish herpes simplex virus type 1 (HSV-1) and/or type 2 (HSV-2) DNA. Additionally, point-of-care is predicted to grow at fastest CAGR during the forecast period owing to the advantages include the relatively reduced cost of kits, quicker turnaround time for tests, the increasing introduction of new kits featuring advanced technology, and the delivery of high-accuracy results.
By application, chlamydia was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the escalating incidence rate is attributed to the growing awareness, the availability of a large number of cost-effective testing products. Being a common ailment, it experiences a higher frequency of testing compared to other diseases. Additionally, HIV/AIDS (Human immunodeficiency virus infection and acquired immune deficiency syndrome) is predicted to grow at fastest CAGR during the forecast period owing to the elevated testing rates, heightened approvals for products such as fourth-generation HIV tests & self-testing kits, substantial research & development efforts in the development of innovative products, and an increasing number of product launches. For instance, in August 2022, The Applied Biosystems HIV-1 Genotyping Kit, developed by Thermo Fisher Scientific Inc., may identify HIV-1 strains that are resistant to drugs.
By end-user, diagnostic centers was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the growing number of patient visits in laboratories where waiting time in comparison to hospitals and clinics is less, the availability of advanced instruments with well-trained professionals is increasing its preference among the general population of some developed regions. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the rising utilization of affordable point-of-care tests for home use is eliminating privacy & stigma concerns associated with sexually transmitted diseases testing in homecare settings and growing launch of novel test kits. For instance, in June 2022, Chembio Diagnostics, Inc. has introduced the SURE CHECK HIV Self-Test in Brazil and the U.K. through online commerce platforms, expanding its accessibility in national pharmacy chains.
North America region is anticipated for the highest revenue share during the forecast period owing to the elevated occurrence of STDs, the abundance of diagnostic companies, an increasing demand for diagnostic procedures, growing encouragement for the innovation & adoption of advanced STI diagnostic tools, therapeutic agents, & other interventions, and a rise in public-private partnerships between market entities & government bodies to enhance the detection of these diseases. For instance, in February 2023, F. Hoffmann-La Roche Ltd. collaborated in a public-private partnership called Lab Networks for Health with the Centers for Disease Control and Prevention. The aim is to enhance the detection, prevention, and treatment of HIV and TB in regions of Africa, Eastern Europe, Central Asia, Latin America, and the Caribbean that have been significantly impacted by these epidemics. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the presence of sophisticated instruments and equipment essential for testing, accompanied by well-trained professionals, the continual introduction of technologically advanced products, increased awareness about these diseases, and a rising trend in launching new products. For instance, in February 2023, Mylab Discovery Solutions Pvt. Ltd. launched three rapid kits for early and fast detection for STIs, which include Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and Syphilis.
Rising approvals of innovative testing products by regulatory authorities is predicted to boost the market growth during the forecast period. Sexually Transmitted Diseases (STDs) are infections resulting from bacteria, viruses, or parasites that are transmitted through various forms of sexual contact, such as vaginal, anal, and oral sex. Additionally, they can be transmitted vertically from mother to child during pregnancy, childbirth, and breastfeeding. The objective of screening is to identify individuals in an apparently healthy population who face an elevated risk of a health issue or condition. This allows for early treatment or intervention, ultimately reducing the incidence and mortality rate within the population. For instance, in May 2022, Abbott's Alinity m STI Assay, capable of detecting and distinguishing four prevalent sexually transmitted infections (STIs), has received approval from the Food and Drug Administration.
By product, consumables was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the rising introduction of innovative solutions and increase in product approvals. For instance, in May 2022, Medmira Inc. has obtained the CE mark for its Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo TP/nTP). This certification empowers the company to enhance its product portfolio in markets that recognize the CE mark. Additionally, instruments & services is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for diagnostic testing kits and surge in research & development activities.
By diagnostic testing, laboratory testing was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the growing patient inclination towards independent clinical laboratories for the diagnosis of these illnesses, and increasing introductions of products in the molecular diagnostics sector enable laboratories to install instruments or equipment based on their specific requirements. For instance, in May 2022, NeuMoDxHSV 1/2 Quant Assay was introduced by Qiagen Inc. with European Commission clearance to measure and distinguish herpes simplex virus type 1 (HSV-1) and/or type 2 (HSV-2) DNA. Additionally, point-of-care is predicted to grow at fastest CAGR during the forecast period owing to the advantages include the relatively reduced cost of kits, quicker turnaround time for tests, the increasing introduction of new kits featuring advanced technology, and the delivery of high-accuracy results.
By application, chlamydia was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the escalating incidence rate is attributed to the growing awareness, the availability of a large number of cost-effective testing products. Being a common ailment, it experiences a higher frequency of testing compared to other diseases. Additionally, HIV/AIDS (Human immunodeficiency virus infection and acquired immune deficiency syndrome) is predicted to grow at fastest CAGR during the forecast period owing to the elevated testing rates, heightened approvals for products such as fourth-generation HIV tests & self-testing kits, substantial research & development efforts in the development of innovative products, and an increasing number of product launches. For instance, in August 2022, The Applied Biosystems HIV-1 Genotyping Kit, developed by Thermo Fisher Scientific Inc., may identify HIV-1 strains that are resistant to drugs.
By end-user, diagnostic centers was the highest revenue-grossing segment in the global sexually transmitted diseases testing market in 2023 owing to the growing number of patient visits in laboratories where waiting time in comparison to hospitals and clinics is less, the availability of advanced instruments with well-trained professionals is increasing its preference among the general population of some developed regions. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the rising utilization of affordable point-of-care tests for home use is eliminating privacy & stigma concerns associated with sexually transmitted diseases testing in homecare settings and growing launch of novel test kits. For instance, in June 2022, Chembio Diagnostics, Inc. has introduced the SURE CHECK HIV Self-Test in Brazil and the U.K. through online commerce platforms, expanding its accessibility in national pharmacy chains.
North America region is anticipated for the highest revenue share during the forecast period owing to the elevated occurrence of STDs, the abundance of diagnostic companies, an increasing demand for diagnostic procedures, growing encouragement for the innovation & adoption of advanced STI diagnostic tools, therapeutic agents, & other interventions, and a rise in public-private partnerships between market entities & government bodies to enhance the detection of these diseases. For instance, in February 2023, F. Hoffmann-La Roche Ltd. collaborated in a public-private partnership called Lab Networks for Health with the Centers for Disease Control and Prevention. The aim is to enhance the detection, prevention, and treatment of HIV and TB in regions of Africa, Eastern Europe, Central Asia, Latin America, and the Caribbean that have been significantly impacted by these epidemics. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the presence of sophisticated instruments and equipment essential for testing, accompanied by well-trained professionals, the continual introduction of technologically advanced products, increased awareness about these diseases, and a rising trend in launching new products. For instance, in February 2023, Mylab Discovery Solutions Pvt. Ltd. launched three rapid kits for early and fast detection for STIs, which include Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and Syphilis.
Segmentation: Sexually Transmitted Diseases Testing Market Report 2023 - 2034
Sexually Transmitted Diseases Testing Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Instruments & Services
- Consumables
Sexually Transmitted Diseases Testing Market Analysis & Forecast by Diagnostic Testing 2023 - 2034 (Revenue USD Bn)
- Point Of Care (PoC) Testing
- Laboratory Testing
Sexually Transmitted Diseases Testing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Syphilis
- Hepatitis B
- Gonorrhea
- Chlamydia
- Genital Herpes
- Human Papillomavirus (HPV)
- HIV/AIDS (Human Immunodeficiency Virus Infection And Acquired Immune Deficiency Syndrome)
- Others
Sexually Transmitted Diseases Testing Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Diagnostic Centers
- Hospitals & Clinics
- Others
Sexually Transmitted Diseases Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Sexually Transmitted Diseases Testing Market: Product Estimates & Trend Analysis
8. Sexually Transmitted Diseases Testing Market: Diagnostic Testing Estimates & Trend Analysis
9. Sexually Transmitted Diseases Testing Market: Application Estimates & Trend Analysis
10. Sexually Transmitted Diseases Testing Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Sexually Transmitted Diseases Testing Market
13. Europe Global Sexually Transmitted Diseases Testing Market
14. Asia Pacific Global Sexually Transmitted Diseases Testing Market
15. Latin America Global Sexually Transmitted Diseases Testing Market
16. MEA Global Sexually Transmitted Diseases Testing Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Hologic Inc.
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- BD
- Bio-Rad Laboratories Inc.
- DiaSorin S.p.A
- Abbott
- bioMerieux Inc.
- Cepheid (Danaher Corporation)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 9.61 Billion |
| Forecasted Market Value ( USD | $ 23.5 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
